Twilight™ · Investigator-Initiated Studies

External Research Program

Evoq Technologies supports ophthalmology, optometry, and vision-research professionals conducting investigator-initiated studies (IIS) with the Twilight™ Dark Adaptometer. These collaborations help validate clinical utility, refine future deployment, and generate real-world evidence on dark adaptation.

Program intent

Independent studies, shared evidence.

Twilight measures how a patient adapts to dark—a functional signal that can precede structural change on imaging. Investigator-initiated work is how that signal is tested across care settings, disease states, and care models.

Evoq does not replace the investigator’s scientific control of the protocol. Support is matched to the study and to available company resources.

Objectives

What these studies ask

  1. 01

    Assess Twilight’s effectiveness in clinical environments and home-use scenarios.

  2. 02

    Document functional visual performance related to dark adaptation across diverse patient populations.

  3. 03

    Assess the clinical and economic value of dark adaptometry in primary eye care practice.

Proposed research domains

Where Twilight can contribute

These domains are priorities, not an exclusive list. Novel questions that use dark-adaptation endpoints are welcome.

Nyctalopia and measurable dysfunction

Correlate patient-reported night-vision complaints with objective dark-adaptation thresholds and recovery kinetics.

Diabetic retinopathy

Evaluate dark adaptation as an early functional test and as a longitudinal monitor in diabetes and diabetic retinopathy.

Early-stage AMD

Study Twilight in early AMD for monitoring treatment response and disease progression alongside structural imaging.

Occupational night-vision screening

Explore screening and safety protocols for professions that depend on reliable night vision.

Teleophthalmology

Integrate dark-adaptation testing into remote visual-health monitoring and distributed care models.

Retinal drug toxicity

Monitor functional change in patients at risk of retinal toxicity from hydroxychloroquine and related agents.

Company support

What Evoq may provide

Depending on the proposed study and available resources, support may include:

  • Availability of the Twilight device for the duration of the study
  • Remote technical and clinical support
  • Data analytics and publication support

Support is not automatic. It is scoped after review of the protocol, timeline, and site capacity.

Investigator commitments

What we expect from investigators

  • Obtain IRB approval and ensure study compliance with applicable regulations.
  • Collect data systematically and ensure rigorous protocol adherence.
  • Prepare and submit study outcomes for peer-reviewed publication or conference presentation.
How to apply

Send a study proposal

Complete the application form. Proposals route to the research team for review.

Open the application